A single i.t. infusion (185 MBq/cm3 of tumour) or three fractionated i.t. infusions to more evenly space activity distribution in the tumour, as well as i.p. injection of anti-vascular endothelial growth factor (VEGF) bevacizumab (Avastin®; Genentech) prior to infusion of the [186Re]Re-BMEDA-PEG-liposomes were studied. Here, VEGFA is linked to neoplasm.